Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of Dabigatran Etexilate (DE) for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Paediatric Patients From Birth to Less Than 2 Years of Age: a Prospective European Non-interventional Cohort Study Based on New Data Collection

NCT05536791 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05536791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05536791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of Dabigatran Etexilate (DE) for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Paediatric Patients From Birth to Less Than 2 Years of Age: a Prospective European Non-interventional Cohort Study Based on New Data Collection
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Withdrawn
Start date
November 24, 2022
Completion date
October 1, 2024
Enrollment
0 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

venous thromboembolism